Join us for Hepatitis C Virus Elimination Symposium: Strategies to Eliminate Hepatitis C as a Public Health Concern in Asia Pacific by 2030
Globally, an estimated 58 million people have chronic hepatitis C virus infection. What strategies can we implement to alleviate this?
Join us for the Hepatitis C Virus (HCV) Elimination Symposium entitled “Strategies to Eliminate Hepatitis C as a Public Health Concern in Asia Pacific by 2030” on 7 Nov, 1pm – 3pm, at Shaw Foundation Alumni House Auditorium, Level 2, NUS, 11 Kent Ridge Drive, Singapore 119244.
The Symposium brings together experts from around the region to discuss key gaps in health policies preventing the APAC region from reaching the target goal of hepatitis C elimination by 2030. It will also enable sharing of best practices and lessons learnt with policymakers and practitioners which in turn can be adapted in their home countries to eliminate Hepatitis C.
For more details, please visit our School’s events page.
Admission is FREE but seating is limited. Please register your interest by Wednesday, 2 November 2022.
*CME/ CPE points pending approval.
For enquiries, please contact Ms Chua Jia Yin at chuajy@nus.edu.sg.
Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.